Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s share price shot up 2% during mid-day trading on Thursday . The company traded as high as $3.59 and last traded at $3.59. 981,404 shares traded hands during trading, a decline of 21% from the average session volume of 1,242,600 shares. The stock had previously closed at $3.52.

A number of research firms have issued reports on ARWR. Jefferies Group LLC reiterated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. Chardan Capital restated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, September 13th. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Piper Jaffray Companies restated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, September 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.06. The business had revenue of $9.34 million during the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Asset Management Americas Inc. boosted its stake in Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 53,500 shares during the last quarter. Virtu KCG Holdings LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 18.0% during the 4th quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 17,201 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 287.9% during the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 88,933 shares in the last quarter. Hedge funds and other institutional investors own 20.61% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/09/21/arrowhead-pharmaceuticals-inc-arwr-shares-up-2.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.